← Leaderboards
Kenneth Westover
Ut Southwestern Medical Center
$1,847,202
Attributed
$1,847,202
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $375.1K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,847,202 · 1
By mechanism
R01$1,847,202 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Adrian Rothenfluh$11,635,213
- Ignacio I. Wistuba$32,209,830
- George E Davis$15,979,966
- Daniel D Billadeau$13,701,310
- Neal Mathew Alto$12,027,869
Others in their field
Other Emerging Leaders on “Grant”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$208,271,537
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
GrantGuanine NucleotidesFutureGenetic ApproachGuanine Nucleotide Exchange FactorsAllosteric RegulationAllelesAffinityBinding SitesCancer TherapyBiochemicalClinicClinical PracticeClinical TranslationCodon NucleotidesColon Cancer PatientsColorectal CancerComplexCancer Clinical TrialDrug DiscoveryEpidermal Growth Factor ReceptorErbb2 GeneExclusion CriteriaGuanosine Triphosphate
Grant awards (5)
Characterization and targeting of rapid nucleotide exchange RAS mutations$356,393
R01 · FY2024 · CA · contact PI
Characterization and targeting of rapid nucleotide exchange RAS mutations$367,647
R01 · FY2023 · CA · contact PI
Characterization and targeting of rapid nucleotide exchange RAS mutations$375,150
R01 · FY2022 · CA · contact PI
Characterization and targeting of rapid nucleotide exchange RAS mutations$374,578
R01 · FY2021 · CA · contact PI
Characterization and targeting of rapid nucleotide exchange RAS mutations$373,434
R01 · FY2020 · CA · contact PI